1. Home
  2. GT vs NTLA Comparison

GT vs NTLA Comparison

Compare GT & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Goodyear Tire & Rubber Company

GT

The Goodyear Tire & Rubber Company

HOLD

Current Price

$9.43

Market Cap

2.0B

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$13.82

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GT
NTLA
Founded
1898
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Automotive Aftermarket
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
GT
NTLA
Price
$9.43
$13.82
Analyst Decision
Hold
Buy
Analyst Count
5
19
Target Price
$10.36
$17.32
AVG Volume (30 Days)
5.7M
6.5M
Earning Date
02-12-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$18,310,000,000.00
$57,528,000.00
Revenue This Year
N/A
$1.96
Revenue Next Year
$0.86
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
33.52
52 Week Low
$6.51
$5.90
52 Week High
$12.03
$28.25

Technical Indicators

Market Signals
Indicator
GT
NTLA
Relative Strength Index (RSI) 58.90 61.88
Support Level $9.43 $13.86
Resistance Level $9.68 $17.09
Average True Range (ATR) 0.26 1.28
MACD 0.01 0.29
Stochastic Oscillator 71.26 52.80

Price Performance

Historical Comparison
GT
NTLA

About GT The Goodyear Tire & Rubber Company

Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment. The company operates its business through three operating segments representing its regional tire businesses: Americas; Europe, the Middle East, and Africa (EMEA); and the Asia Pacific.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: